Skip to main content
. Author manuscript; available in PMC: 2023 Apr 14.
Published in final edited form as: Neurocrit Care. 2022 Sep 27;38(2):345–355. doi: 10.1007/s12028-022-01599-9

Figure 1. Patient Selection.

Figure 1.

Patient selection, excluded patients, and included patients stratified into unweighted cohorts and weighted cohorts based on levetiracetam dosing group (≤1000 mg/day, 1500 mg/day, and ≥2000 mg/day).